



Emmanuel Caeymaex

Executive Vice President

Chief Commercial Officer & Head of Patient Impact

Joined UCB in March 1994

Appointed in 2015

Date of birth: 1969

Nationality: Belgian

Introduction & Professional experience

Emmanuel leads the worldwide commercialization of all UCB's innovative solutions, ensuring rapid and sustainable access to medicines that create unique value for people living with severe diseases such as rare epileptic syndromes, rare neuromuscular disorders, auto-immune dermatology and rheumatology, and musculoskeletal diseases.

As a leader at UCB, Emmanuel is dedicated to enhancing patient experience and championing health equity, fostering an inclusive environment where colleagues can excel while growing personally and professionally. With strong execution of global launches, he is looking to support UCB in its decade of growth that will drive innovation and deliver meaningful moments for those the company serves.

Emmanuel has been instrumental in advancing UCB's transformation into a global biopharma company focused on patients with severe diseases. Prior to his most recent appointment he led UCB's Immunology Solutions unit, also directly running UCB's US operations and formerly UCB's main cross functional asset team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011. He previously contributed to build UCB's leadership position in epilepsy, in global marketing and business unit leadership positions. Prior to 1999, Emmanuel established and ran UCB's operations in several Asia-Pacific markets for which he was awarded as Laureate of the Prince Albert Fund.

Education

Emmanuel received a Business Engineer MSc degree from the University of Louvain (UCL), Belgium, a Master's in International Management from the Community of European Management Schools (CEMS) and continued his executive leadership development journey at INSEAD.

Main external appointments

President, Prince Albert Fund, Brussels.

